Explore the latest news from Khondrion and its team.
NIJMEGEN, the Netherlands – Wednesday February 5th, 2020: Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies...
Study will examine impact on cognitive function from one of the most advanced disease-modifying drug treatments for mitochondrial disease in...
Khondrion becomes partner in DuSRA-VOILA collaboration
On Friday 10th January 2020, CEO Jan Smeitink participated in the Annual MitoAction Town Hall Meeting alongside other companies and organisations,...
Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces...
Members of the Khondrion team will be attending Mitochondrial Medicine 2019 on 11-13 December 2019. The event will bring together...
How did you cross paths with Khondrion? I heard about Khondrion from International Mito-Patients, the global network of patient organisations, and...
When did Sam first start experiencing symptoms and how long did it take for him to be diagnosed? Sam was first diagnosed with mitochondrial disease...
How did you cross paths with Khondrion? I have crossed paths with Jan Smeitink, Khondrion’s CEO and Founder, multiple times at various international...
When did you first start experiencing mitochondrial disease symptoms and how long did it take to get your diagnosis? I had a very happy and...
How did you cross paths with Khondrion? I heard about Khondrion from international colleagues and was made aware that this company was focused on...